OBJECTIVE: To compare the efficacy of a 10-day and a 4-month doxycylcine course for the treatment of Chlamydia trachomatis-reactive arthritis (Ct-ReA). METHODS:Patients with active Ct-ReA were enrolled in a prospective, multicentre, double-blind, controlled clinical trial and randomised to receive doxycycline 100 mg twice daily for 10 days followed either by placebo or by continued doxycycline 100 mg twice daily over 4 months. Various clinical and laboratory parameters referring to disease activity were recorded in the beginning and at the end of treatment. RESULTS:32 of 37 patients included (15 men and 17 women; mean (standard deviation) disease duration 17 (13) months completed the study; 17 were randomised to short-term doxycycline and placebo (placebo group) and 15 to prolonged treatment with doxycycline (doxycycline group) over the 4-month study period. After this time, only two patients from each group went into remission. There were no drop-outs owing to adverse events or treatment failures. CONCLUSIONS: The results of this study suggest that prolonged treatment with a 4-month course of doxycycline is not superior to short-term treatment over 10 days in patients with Ct-ReA.
RCT Entities:
OBJECTIVE: To compare the efficacy of a 10-day and a 4-month doxycylcine course for the treatment of Chlamydia trachomatis-reactive arthritis (Ct-ReA). METHODS:Patients with active Ct-ReA were enrolled in a prospective, multicentre, double-blind, controlled clinical trial and randomised to receive doxycycline 100 mg twice daily for 10 days followed either by placebo or by continued doxycycline 100 mg twice daily over 4 months. Various clinical and laboratory parameters referring to disease activity were recorded in the beginning and at the end of treatment. RESULTS: 32 of 37 patients included (15 men and 17 women; mean (standard deviation) disease duration 17 (13) months completed the study; 17 were randomised to short-term doxycycline and placebo (placebo group) and 15 to prolonged treatment with doxycycline (doxycycline group) over the 4-month study period. After this time, only two patients from each group went into remission. There were no drop-outs owing to adverse events or treatment failures. CONCLUSIONS: The results of this study suggest that prolonged treatment with a 4-month course of doxycycline is not superior to short-term treatment over 10 days in patients with Ct-ReA.
Authors: J Sieper; C Fendler; S Laitko; H Sörensen; C Gripenberg-Lerche; F Hiepe; R Alten; W Keitel; A Groh; J Uksila; U Eggens; K Granfors; J Braun Journal: Arthritis Rheum Date: 1999-07
Authors: U Dreses-Werringloer; I Padubrin; B Jürgens-Saathoff; A P Hudson; H Zeidler; L Köhler Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191
Authors: A M Beutler; A P Hudson; J A Whittum-Hudson; W A Salameh; H C Gerard; P J Branigan; H R Schumacher Journal: J Clin Rheumatol Date: 1997-06 Impact factor: 3.517
Authors: J D Carter; L R Espinoza; R D Inman; K B Sneed; L R Ricca; F B Vasey; J Valeriano; J A Stanich; C Oszust; H C Gerard; A P Hudson Journal: Arthritis Rheum Date: 2010-05
Authors: Antti Kuuliala; Heikki Julkunen; Leena Paimela; Ritva Peltomaa; Hannu Kautiainen; Heikki Repo; Marjatta Leirisalo-Repo Journal: Rheumatol Int Date: 2013-06-20 Impact factor: 2.631
Authors: Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch Journal: Cochrane Database Syst Rev Date: 2019-09-26
Authors: Tim T A Bender; Judith Leyens; Julia Sellin; Dmitrij Kravchenko; Rupert Conrad; Martin Mücke; Matthias F Seidel Journal: Orphanet J Rare Dis Date: 2020-10-31 Impact factor: 4.123